Renal cell carcinoma

Renal cell carcinoma
Name	Renal cell carcinoma
Field	Oncology, Nephrology
Symptoms	Hematuria, flank pain, palpable mass
Complications	Metastasis to lung, bone, liver, brain
Onset	Adults, peak 60s
Risks	Smoking, obesity, hypertension, von Hippel–Lindau disease
Diagnosis	Imaging, biopsy, histopathology
Treatment	Nephrectomy, targeted therapy, immunotherapy
Frequency	~2–3% of adult malignancies

Renal cell carcinoma is the most common type of kidney cancer arising from the renal tubular epithelium. It typically presents in middle-aged to older adults and may follow insidious onset with localized or systemic manifestations. Clinical management integrates imaging, surgical resection, targeted molecular agents, and immune checkpoint inhibitors coordinated by multidisciplinary teams.

Signs and symptoms

Patients often report painless gross Hematuria alongside flank pain and a palpable mass in advanced cases; paraneoplastic phenomena such as polycythemia or hypercalcemia may occur. Constitutional features include weight loss, fever, and night sweats that can mimic presentations in Hodgkin lymphoma, Non-Hodgkin lymphoma, or Chronic fatigue syndrome cohorts. Metastatic spread commonly produces respiratory symptoms from pulmonary lesions and bone pain from osseous involvement seen in referrals to Orthopaedic surgery and Radiation oncology services. Rarely, tumor thrombus extends into the renal vein and inferior vena cava causing signs evaluated with protocols developed at tertiary centers like Mayo Clinic and Cleveland Clinic.

Causes and risk factors

Established environmental risks include cigarette smoking, obesity, and long-standing hypertension recognized in epidemiologic investigations by institutions such as the World Health Organization and Centers for Disease Control and Prevention. Occupational exposures investigated in cohorts from National Institutes of Health studies implicate asbestos and certain petroleum byproducts; associations have been reported in populations near industrial sites regulated by the Environmental Protection Agency. Hereditary syndromes account for familial clustering: germline mutations in the VHL tumor suppressor underlie von Hippel–Lindau disease with links to management guidelines from National Cancer Institute consortia. Other genetic predispositions involve MET proto-oncogene in hereditary papillary RCC and fumarate hydratase alterations in hereditary leiomyomatosis and renal cell cancer surveilled in genetics clinics associated with Johns Hopkins Hospital.

Pathophysiology and histology

Tumorigenesis often follows inactivation of tumor suppressors and activation of oncogenic pathways; loss of VHL function leads to upregulation of hypoxia-inducible factors and aberrant angiogenesis targeted by drugs developed by pharmaceutical companies such as Roche and Novartis. Clear cell histology—characterized by lipid- and glycogen-rich cytoplasm—constitutes the majority of cases and is distinguished at pathology departments affiliated with Mayo Clinic and Memorial Sloan Kettering Cancer Center. Papillary, chromophobe, and collecting duct subtypes show distinct morphologies and molecular signatures comparable to classifications from the World Health Organization tumor taxonomy. Tumor microenvironment interactions with immune checkpoints such as PD-1/PD-L1 underpin rationale for therapies conceptualized through clinical trials at Dana-Farber Cancer Institute and MD Anderson Cancer Center.

Diagnosis and staging

Initial evaluation relies on cross-sectional imaging—contrast-enhanced computed tomography and magnetic resonance imaging—performed at radiology units like those at Massachusetts General Hospital and UCLA Medical Center. Ultrasound can differentiate cystic from solid lesions in outpatient settings associated with Mayo Clinic Health System. Percutaneous biopsy interpreted by surgical pathologists at centers including Johns Hopkins Hospital may be used when systemic therapy is considered. Staging follows the TNM classification promulgated by the Union for International Cancer Control and integrates tumor size, nodal involvement, and distant metastasis; staging informs referral to surgical oncology and medical oncology teams at tertiary centers such as Memorial Sloan Kettering Cancer Center.

Treatment

Localized tumors are managed primarily with partial or radical nephrectomy, techniques refined in training programs at institutions like Cleveland Clinic and Stanford Health Care. Minimally invasive options—laparoscopic or robotic-assisted nephrectomy—are provided in high-volume centers including Mayo Clinic and Johns Hopkins Hospital. Ablative therapies such as cryoablation and radiofrequency ablation are alternatives for select patients treated at centers like MD Anderson Cancer Center. For advanced or metastatic disease, targeted therapies against VEGF and mTOR pathways (agents developed by Pfizer and AstraZeneca) and immune checkpoint inhibitors (investigated in trials led by NCI and pharmaceutical collaborators) are standard. Multimodality care may include stereotactic radiosurgery for brain metastases at institutions such as Barrow Neurological Institute and palliative interventions coordinated with Hospice services.

Prognosis and epidemiology

Prognosis depends on stage, grade, histologic subtype, and performance status; localized disease has favorable outcomes after nephrectomy, while metastatic disease historically carried poor survival until improvements from targeted and immunotherapies reported in trials conducted by European Organisation for Research and Treatment of Cancer and SWOG. Incidence shows geographic variation with higher rates in North America and parts of Europe documented by the Global Burden of Disease Study and surveillance registries like SEER Program. Mortality trends have shifted with earlier detection through imaging practiced in hospitals such as Mayo Clinic and evolving systemic therapies developed by multinational consortia including ESMO and ASCO.

Category:Kidney cancer